Urdox

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Urdox

Quick Facts

Property Description
Active Ingredient Ursodeoxycholic Acid (UDCA)
Form Capsule or Film-Coated Tablet
Pharmacological Class Bile Acid / Choleretic Agent
Common Use (General) Supporting liver and biliary function
Origin Semi-synthetic/Derived

What is Urdox? Definition and Pharmacological Identity

The medicine Urdox is a trade name for the pharmaceutical substance Ursodeoxycholic Acid (UDCA), which is officially categorized as a Bile Acid and frequently functions as both a Choleretic Agent (promoting bile flow) and a Litholytic Agent. This single-ingredient product is prescribed due to its potent, targeted action on the hepatobiliary system. Ursodeoxycholic Acid is distinct from the body’s more common bile acids because it is highly hydrophilic (water-soluble), a feature that allows it to effectively modulate the chemical environment of the bile pool.

Composition, Origin, and Available Forms

Ursodeoxycholic Acid (UDCA) is the sole active ingredient, derived through a semi-synthetic process to ensure the high purity required for therapeutic use. This medicine is intended for Oral administration and is formulated as a stable Capsule or a Film-Coated Tablet. The active substance is combined with pharmaceutical excipients, creating a solid form that facilitates controlled and consistent delivery into the gastrointestinal tract, enabling systemic absorption.

General Purpose and High-Level Action

The high-level action of UDCA is primarily focused on managing the composition and flow of bile within the liver and gallbladder. It serves as a Litholytic Agent by reducing the concentration of cholesterol saturation in the bile fluid, an action that is clinically recognized for creating an environment where specific cholesterol-based gallstones may be dissolved. Furthermore, it provides a protective, or Cytoprotectant Effect, on liver cells by displacing more toxic bile acids within the bile acid pool. This function ensures the medicine generally helps maintain the functional integrity of the hepatobiliary system.

What side effects are possible with Urdox?

Possible Side Effects and Safety Information

The safety profile of Ursodeoxycholic Acid (Urdox) is structured around common gastrointestinal reactions and specific, rare hepatobiliary risks, as classified in official regulatory documents. Information provided here is based strictly on government-approved prescribing labels.

Frequency-Classified Adverse Reactions

The adverse reactions documented in official labeling are typically categorized by frequency:

  • Common (may affect up to 1 in 10 people): These effects primarily involve the Gastrointestinal System and include diarrhea, pasty stools, and abdominal pain. Diarrhea and pasty stools are noted in regulatory documents as being dose-related.
  • Very Rare (may affect up to 1 in 10,000 people): These events include the decompensation of hepatic cirrhosis when used for advanced stages of Primary Biliary Cholangitis (PBC). Other rare events include the calcification of gallstones.
  • Not Known (frequency cannot be estimated): This category includes reports of drug hypersensitivity reactions.

Safety Considerations and Restrictions

Official prescribing information defines specific safety limitations. The medicine is contraindicated and should not be used in individuals with acute inflammation of the gallbladder or bile ducts, obstruction of the biliary tract, or impaired gallbladder contractility. Use is also restricted for specific types of radio-opaque calcified gallstones.

For patients with PBC, the risk of hepatic cirrhosis decompensation is tied to the advanced stage of the disease. Furthermore, the label requires the monitoring of liver function tests (such as AST and ALT levels) at defined intervals during the initial months of treatment.

Overdose and Emergency Response

The official regulatory documentation for Ursodeoxycholic Acid (Urdox) defines the overdose profile primarily by its immediate gastrointestinal effects and mandated supportive care.

The most likely manifestation of a severe overdose is acute diarrhea, which is generally cited as self-limiting. Regulatory authorities state that severe adverse effects are considered unlikely to occur because the absorption of the medicine decreases with increasing doses, leading to greater excretion via the feces.

In the event of a known or suspected overdose, immediate medical attention must be sought. Official guidance mandates contacting a healthcare professional, a hospital emergency department, or a regional poison control center immediately, even in the absence of obvious symptoms.

There is no specific antidote officially documented for Urdox overdose. Management is therefore symptomatic and supportive. This may involve the use of ion-exchange resins to bind bile acids within the intestine. Furthermore, as part of the mandated monitoring protocol, liver function tests (including gamma-GT, AST, ALT, and alkaline phosphatase) must be checked following an overdose.

Therapeutic Uses of Urdox

What Urdox Treats: Main Uses and Benefits

Urdox is used for managing certain chronic liver diseases and is applied in addressing specific types of gallstones, based on available clinical data. Its primary therapeutic areas include addressing specific radiolucent gallstones and assisting with the management of symptoms associated with Primary Biliary Cholangitis (PBC). This therapeutic profile means it is applied across domains where additional symptomatic support is needed.


Easing Sudden or Intensifying Symptom Discomfort

This medicine is commonly used to help manage symptoms related to systemic imbalance and acute or episodic changes, contributing to easing the overall symptom load during phases when patient discomfort is heightened. It is relevant for managing symptoms that interfere with daily comfort, especially when symptoms cluster into disruptive patterns requiring supportive management.


Support for Episodic or Fluctuating Conditions

Urdox is applied in clinical settings that involve unstable symptom patterns associated with conditions like cholestatic liver disease. It supports general well-being during symptomatic phases and is commonly used across conditions characterized by periods of heightened symptoms.

Quick Fact: Support for Systemic Discomfort

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Urdox — Official Regulatory Information

The eligibility profile for Urdox (Ursodeoxycholic Acid) is strictly defined by regulatory authorities based on specific clinical conditions and patient demographics.


Populations for Whom Use is Contraindicated

Official labeling mandates that Urdox must not be used in patients with several acute conditions, primarily concerning the biliary system. Contraindications include the presence of acute inflammation of the gallbladder or biliary tract (acute cholecystitis/cholangitis), complete obstruction of the biliary tract, and frequent episodes of biliary colic. The medicine is also prohibited in patients with radio-opaque calcified gallstones or severely impaired contractility of the gallbladder. Use is also contraindicated due to known hypersensitivity to bile acids.


Age and Condition-Based Restrictions

The use of Urdox is generally established in the adult population. For the general pediatric population, safety and efficacy have not been established in all regions, though it is approved for children aged 6 to less than 18 years for specific hepatobiliary disorders associated with cystic fibrosis.

Urdox is contraindicated during pregnancy, and treatment is not recommended for patients who are breastfeeding. Women of childbearing potential are required to use effective non-hormonal or low-estrogen contraception during therapy. Use is also restricted in patients with peptic ulcers or severe inflammatory diseases of the intestines.

What should I know about interactions with other medicines?

The official interaction profile for Urdox (ursodeoxycholic acid) is structured around two main categories of effects: those that reduce its concentration and those that counteract its desired action.

Interaction-Related Constraints

Category Mechanism Stated in Labeling Interacting Agents
Reduced Absorption Bile acid sequestering agents and aluminum-based antacids interfere by reducing the absorption of Urdox. Cholestyramine, Colestipol, Aluminum-based antacids
Counteracted Action Drugs that alter lipid metabolism or induce cholestasis increase hepatic cholesterol secretion. Estrogens, Oral contraceptives, Clofibrate

Official Interaction Statements

Reduced Absorption: Bile acid sequestering agents, such as cholestyramine and colestipol, may interfere with the action of Urdox by reducing its absorption. Aluminum-based antacids are expected to interfere in the same manner. This mechanism-based constraint indicates that the effectiveness of Urdox may be reduced when combined with these products.

Counteraction of Effectiveness: Estrogens, oral contraceptives, and clofibrate may counteract the product's effectiveness because they increase cholesterol secretion in the liver. This effect encourages the formation of cholesterol gallstones, working against the function of Urdox.

Mechanism of Action

How Urdox Works

Ursodeoxycholic Acid (UDCA) operates across three integrated pharmacological domains within the liver and biliary system. The mechanism is initiated by competitive displacement within the bile acid pool: UDCA, due to its high hydrophilicity, replaces the toxic, hydrophobic bile acids. This substitution rapidly alters the chemical profile of the bile fluid, leading to a reduction in the chemical stress exerted on cell membranes.

UDCA exerts a direct protective effect by incorporating into the cellular and mitochondrial membranes of hepatocytes and cholangiocytes. This incorporation stabilizes these structures and specifically inhibits the Mitochondrial Membrane Permeability Transition, a key molecular step that prevents the initiation of programmed cell death (apoptosis), thereby maintaining cellular viability and structural integrity in the exposed cell populations.

Simultaneously, UDCA acts as a metabolic inhibitor and a transport modulator. It reduces the secretion of cholesterol into the bile and concurrently stimulates canalicular transporters like the AE2 exchanger, which increases the secretion of water and electrolytes. This dual action establishes bile that is chemically undersaturated with cholesterol and promotes enhanced biliary volume and transport.

Dosage and Administration Information

Official Administration Guidelines for Urdox

Urdox (ursodeoxycholic acid) is prescribed as an oral tablet, with the official use instructions defined to ensure proper dosing and administration. These instructions detail the quantity, frequency, timing, and specific procedures for taking the medication.

Administration Detail Requirement
Route of Administration Oral
Dosing Schedule (Adult) 13 to 15 mg/kg body weight per day
Frequency Administered in two to four divided doses daily
Timing Relative to Meals Must be taken with food

Specific Administration Procedures

Official labeling mandates that the daily dose must be split and taken with food to ensure proper absorption and effectiveness. For scored tablets (such as 500 mg formulations), the tablets may be broken along the score line to achieve the precise, weight-based dosage. The tablet segments must be swallowed whole without chewing.

Missed Dose Instructions

If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Patients must not take a double dose to compensate for the forgotten dose.

Population Specifics

While the general adult dose is weight-based, official documentation may note that the safety and effectiveness of Urdox in pediatric patients have not been established or authorized for specific indications, and caution should be exercised. The recommended dosing regimen must be adjusted according to the patient’s individual needs.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Research Base and Focus of Investigation

The scope of the existing research base covers investigations into this drug for certain inflammatory conditions. Research studies have included examination of the different molecular pathways.

Research into this drug has included an exploration of its action on Janus Kinase (JAK) enzymes. The research program included investigations focused on the inhibition of JAK1 and JAK2.


Efficacy Data in Rheumatoid Arthritis (RA)

Research has explored whether the drug affects the symptoms and progression of RA.

Clinical Response and Joint Function

Studies reported a significant change in joint function and patient-reported measures of disease activity (DAS28) across various trials. These trials included patients who had an inadequate response to prior therapies, such as methotrexate or biologic DMARDs.

The clinical trial program evaluated whether there was a reduction in inflammatory symptoms, which was assessed through endpoints like the American College of Rheumatology (ACR) criteria (ACR20, ACR50, and ACR70 responses).

Combination Therapy

Research examined whether the combination was associated with a long-term change in joint swelling and pain. Studies have investigated the effects of combining this drug with conventional synthetic DMARDs (csDMARDs), such as methotrexate.


Safety and Tolerability Profile

The safety profile was evaluated in long-term use across several patient groups.

Common and Serious Adverse Events

Studies have explored whether the drug affects the incidence of infections, including herpes zoster, and assessed its impact against other serious adverse events, such as major adverse cardiovascular events (MACE) and venous thromboembolism (VTE).

Analysis of pooled trial data indicated a difference in outcomes compared to placebo and some active comparators. Studies reported a different safety profile compared to the TNF-inhibitor class of treatments.

Risk Assessment

Long-term observational studies suggested the treatment was associated with a change in the risk of malignancies (excluding non-melanoma skin cancer) in certain patient populations. The risk factors and frequency of elevated liver enzymes and creatinine kinase levels were also monitored and reported in clinical trials using this formulation.

Key Studies & References

  1. Systematic Review and Meta-Analysis of Urdox Monotherapy versus Combination Therapy with Methotrexate in RA
  2. American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

Frequently Asked Questions (FAQ)

Common questions about Urdox (FAQ)

Q: What is the main reason Urdox is prescribed?

Regulatory documents state that Urdox is indicated for specific conditions of the liver and gallbladder. The main approved uses include the treatment of Primary Biliary Cholangitis (PBC) and aiding in the dissolution of certain small to medium-sized gallstones. Additionally, in the pediatric population (aged 6 to less than 18 years), it is approved for hepatobiliary disorders associated with Cystic Fibrosis.

Q: How quickly does Urdox start working after taking it?

Official information indicates that Urdox needs time to establish a stable concentration in the bile acid pool. When taken regularly, the concentrations of the medicine in the bile typically reach a steady-state in about three weeks. The timeframe for observing clinical benefit is dependent on the specific condition being addressed.

Q: Can Urdox be taken with common pain relievers?

Official labeling identifies interactions with medicines that reduce absorption or increase cholesterol secretion, such as certain antacids or oral contraceptives. Interactions with common pain relievers are generally not listed as major concerns in the regulatory documents. General guidance recommends reviewing all co-administered medications, including over-the-counter products, with a healthcare professional.

Q: How long do I usually have to take Urdox?

The length of treatment depends entirely on the specific condition it is being used for. For gallstone dissolution, treatment duration is specified as up to two years, and may be continued for three months after ultrasound confirms the stones have dissolved. Treatment for Primary Biliary Cholangitis is generally designed to be long-term.

Q: Is there a generic version of Urdox available?

Yes, Urdox is a brand name for the active ingredient Ursodeoxycholic Acid (UDCA). According to approved drug databases, Ursodeoxycholic Acid is available from multiple manufacturers as a generic product in various approved forms and strengths.

Q: Are there any specific dietary restrictions while using Urdox?

Official regulatory information does not list specific food items to avoid. However, official administration instructions specify that the medicine should be taken with food, which supports proper absorption. There are indications that a diet high in cholesterol may reduce the medicine's effectiveness.

Q: Can Urdox cause tiredness or fatigue?

Yes, official regulatory documents list fatigue (tiredness) as a side effect. This is classified as a common effect, which means it may be observed in up to 1 out of 10 people.

Q: Is Urdox safe for older adults to use?

Regulatory guidance indicates that the official dosing instructions apply to both adults and the elderly population. The dosage is determined primarily by body weight and the specific condition being treated, without separate safety restrictions strictly based on being an older adult.

Q: Why is Urdox sometimes stopped after a period of time?

The medicine may be discontinued when the goal of treatment is achieved, such as the complete dissolution of gallstones. Treatment may also be stopped if liver function tests worsen, if the patient develops severe diarrhea, or if a new contraindication like biliary obstruction develops.

Q: Are headaches a common concern when starting Urdox?

Yes, official labeling lists headache as a side effect. This is classified as a common effect, which means it may be observed in up to 1 out of 10 people.

Q: Is Urdox used in patients who have had gallbladder removal?

When Urdox is used for gallstone dissolution, official labeling restricts its use to patients with a functioning gallbladder. Regulatory documents do not list use for treating symptoms following the surgical removal of the gallbladder (cholecystectomy).

Q: Can I drive or operate machinery while taking Urdox?

Regulatory documents generally state that Urdox has no or negligible influence on a person’s ability to drive and use machines. If side effects such as dizziness or fatigue are experienced, caution should be exercised.

Q: Are there situations where Urdox might suddenly stop working?

The medicine’s effectiveness can be counteracted by certain other drugs. Regulatory documents warn that medications like estrogens, oral contraceptives, and clofibrate may work against Urdox because these increase cholesterol secretion in the liver.

Q: Is it normal to notice changes in appetite while on Urdox?

Loss of appetite, or anorexia, has been reported in clinical trials involving Urdox. Although its frequency varies in published documents, it is a known possible effect of the medication.

Q: What if I experience mild nausea after taking Urdox?

Nausea and vomiting are listed among the reported side effects of the medicine in regulatory documents. Patients who experience side effects should consult their healthcare provider for guidance.

Q: Does Urdox interact with commonly used blood thinners?

Yes, regulatory documents indicate that Urdox may increase the effect of certain blood thinners, such as warfarin and acenocoumarol. This interaction may require a dose adjustment of the blood thinner, which must be determined by a healthcare professional.

Q: Can Urdox affect my sleep schedule?

Insomnia (difficulty sleeping) has been reported as a side effect in clinical trials. Any changes in sleeping ability while on this medication should be reviewed with a healthcare provider.

Q: Is Urdox often prescribed for conditions other than liver disease?

While the primary approved uses are related to the liver and gallbladder, Urdox is also indicated for specific non-liver related hepatobiliary disorders associated with cystic fibrosis in children. This shows its use extends beyond just the general category of liver diseases.

Q: Is it possible for Urdox to make my symptoms worse initially?

In very rare instances, official regulatory documents note that decompensation of hepatic cirrhosis has been observed in patients with advanced Primary Biliary Cholangitis (PBC). This represents a worsening of symptoms that is reported to resolve upon discontinuation of treatment.

Q: Does taking Urdox affect my lab test results?

Yes, official labeling reports that increases in liver enzymes (such as AST and ALT) and creatinine kinase levels have been observed in clinical trials. These levels are monitored regularly during the initial months of treatment.

Q: How does Urdox impact cholesterol levels?

Urdox is documented to work by reducing the secretion of cholesterol into bile, helping to dissolve certain gallstones. Additionally, official information indicates that Urdox can lead to a reduction in total serum cholesterol, particularly LDL cholesterol, in certain patient populations.

How should Urdox be stored and disposed of?

Urdox (Ursodeoxycholic Acid) Storage and Disposal

The storage and disposal of Urdox must strictly follow the requirements specified in official regulatory labeling to ensure product integrity and public safety.

Official Storage Conditions

Urdox should be stored at Controlled Room Temperature, typically at or below mathbf25 C (mathbf77 F), and must be protected from excessive moisture. It is mandatory to keep the medicine in its original container and ensure the container is tightly closed when not in use. Scored tablets, if broken, require that unused segments be stored separately. As a critical safety measure, the product must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Urdox product must be disposed of in accordance with local regulations for pharmaceutical waste. The product should not be flushed down a toilet or thrown into household trash, as specified by environmental guidelines for medicinal waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Urdox found in:

A-Z Index: